CIK 0001730430 · Large accelerated filer
Kiniksa Pharmaceuticals International, plc
Sign in to watch- Ticker
- KNSA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981795578
- Phone
- 7814319100
- Business address
- 105 PICCADILLY, SECOND FLOOR, LONDON, United Kingdom, W1J 7NJ
- Former names
- Kiniksa Pharmaceuticals, Ltd.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $78,588,440
- in 8 filings, $78.6M under 10b5-1 plans
Net −$78,588,440. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Patel Sanj K −$51.7M CHAIRMAN & CEO sold 42% of stake
- Moat Ross −$9.6M CHIEF OPERATING OFFICER sold 91% of stake
- Paolini John F. −$8.9M CHIEF MEDICAL OFFICER sold 58% of stake
- Megna Michael R −$4.9M CHIEF ACCOUNTING OFFICER sold 80% of stake
- Ragosa Mark −$3.4M CHIEF FINANCIAL OFFICER sold 64% of stake
Reading 59 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-02 | Moat Ross CHIEF OPERATING OFFICER | Option exercise 10b5-1 | +6,263 | $22.89 | $143K | 38,271 |
| 2026-11-02 | Moat Ross CHIEF OPERATING OFFICER | Sale 10b5-1 | −6,681 | $91.23 | $610K | 31,590 |
| 2026-11-02 | Moat Ross CHIEF OPERATING OFFICER | Sale 10b5-1 | −8,932 | $92.05 | $822K | 22,658 |
| 2026-11-02 | Moat Ross CHIEF OPERATING OFFICER | Sale 10b5-1 | −11,642 | $93.15 | $1.1M | 11,016 |
| 2026-11-02 | Moat Ross CHIEF OPERATING OFFICER | Sale 10b5-1 | −722 | $94.05 | $68K | 10,294 |
| 2026-11-02 | Moat Ross CHIEF OPERATING OFFICER | Option exercise · Share Option 10b5-1 | −9,412 | 15,793 | ||
| 2026-11-02 | Moat Ross CHIEF OPERATING OFFICER | Option exercise · Share Option 10b5-1 | −12,302 | 27,062 | ||
| 2026-11-02 | Moat Ross CHIEF OPERATING OFFICER | Option exercise · Share Option 10b5-1 | −6,263 | 1,691 | ||
| 2026-11-02 | Ragosa Mark CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +9,636 | $10.76 | $104K | 30,490 |
| 2026-11-02 | Ragosa Mark CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +5,388 | $11.10 | $60K | 35,878 |
| 2026-11-02 | Ragosa Mark CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +12,123 | $11.97 | $145K | 48,001 |
| 2026-11-02 | Ragosa Mark CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +9,636 | $17.76 | $171K | 57,637 |
| 2026-11-02 | Ragosa Mark CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −14,027 | $91.40 | $1.3M | 43,610 |
| 2026-11-02 | Ragosa Mark CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −10,502 | $92.03 | $966K | 33,108 |
| 2026-11-02 | Ragosa Mark CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −12,034 | $93.13 | $1.1M | 21,074 |
| 2026-11-02 | Ragosa Mark CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −220 | $94.01 | $21K | 20,854 |
| 2026-11-02 | Ragosa Mark CHIEF FINANCIAL OFFICER | Option exercise · Share Option 10b5-1 | −9,636 | 4,380 | ||
| 2026-11-02 | Ragosa Mark CHIEF FINANCIAL OFFICER | Option exercise · Share Option 10b5-1 | −5,388 | 0 | ||
| 2026-11-02 | Ragosa Mark CHIEF FINANCIAL OFFICER | Option exercise · Share Option 10b5-1 | −12,123 | 0 | ||
| 2026-11-02 | Ragosa Mark CHIEF FINANCIAL OFFICER | Option exercise · Share Option 10b5-1 | −9,636 | 8,760 |
Page 2 of 74 · 1,467 trades